Abstract
With the limited resources available, healthcare purchasers need to be able to determine the value of the pharmaceuticals or healthcare interventions that they purchase and their beneficiaries receive. From a purchaser’s perspective, at least part of the benefit resulting from interventions may be the associated decreased lost productivity among their beneficiaries. However, the ability to value lost productivity at a population level is dependent on the availability of productivity data. This review provides a taxonomy of productivity measures within the currently available, national databases and surveys within the USA that capture lost productivity data. As the field of productivity measurement matures, with more precise data and methods to estimate patients’ lost productivity in national survey data, healthcare employers and policy-makers will be able to make better-informed decisions concerning the medications that have an impact on the effects of diseases at a population level.